SCHEMBL498930

SCHEMBL498930

Nc1ccc2c(c1O)C(=O)c1c(ccc(N)c1O)C2=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.52
MEN1 O00255 6/20 0.52
KMT2A Q03164 6/20 0.52
ALDH1A1 P00352 5/20 0.52
MAOA P21397 5/20 0.52
TDP1 Q9NUW8 5/20 0.52
THRB P10828 4/20 0.52
MAPK1 P28482 4/20 0.52
HPGD P15428 4/20 0.52
APEX1 P27695 3/20 0.52
RECQL P46063 3/20 0.52
ALOX15 P16050 3/20 0.52
HSD17B10 Q99714 3/20 0.52
CSNK2A2 P19784 2/20 0.52
CSNK2B P67870 2/20 0.52
CSNK2A1 P68400 2/20 0.52
CSNK2A3 Q8NEV1 2/20 0.52
KDM4E B2RXH2 2/20 0.52
CYP3A4 P08684 2/20 0.52
DYRK1A Q13627 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10719074 0.88 MAOA (0.71) MAPTMEN1KMT2AALDH1A1MAOA
SCHEMBL31026205 0.88 MEN1 (0.67) MAPTMEN1KMT2AALDH1A1MAOA
SCHEMBL397172 0.88 MEN1 (0.67) MAPTMEN1KMT2AALDH1A1MAOA
SCHEMBL498583 0.85 CSNK2A2 (0.71) MAPTMEN1KMT2AALDH1A1MAOA
SCHEMBL18984692 0.83 ALDH1A1 (0.56) MAPTMEN1KMT2AALDH1A1MAOA
SCHEMBL18857577 0.82 MAOA (0.80) MAPTMEN1KMT2AALDH1A1MAOA
SCHEMBL7915144 0.81 MAOA (0.68) MAPTMEN1KMT2AALDH1A1MAOA
SCHEMBL6904748 0.76 MAPT (0.83) MAPTMEN1KMT2AALDH1A1MAOA
SCHEMBL10949445 0.70 ALDH1A1 (0.67) MAPTMEN1KMT2AALDH1A1MAOA
SCHEMBL11297406 0.70 ELANE (0.53) MAPTMEN1KMT2AALDH1A1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379109-B1 COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE BAUSCH HEALTH COMPANIES INC (CA) 2020-10-07 EP disclosed
US-20160205925-A1 ANTIMICROBIAL COMPOSITIONS MADE OF A THERMOPLASTIC POLYMER AND A PHOTOSENSITIZER ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) 2016-07-21 US disclosed
US-9226917-B2 Photodynamic therapy for conditions of the eye VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) 2016-01-05 US disclosed
US-8968715-B2 Drug delivery systems for photodynamic therapy THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2015-03-03 US disclosed
US-8852629-B2 Drug delivery system for hydrophobic drugs VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) 2014-10-07 US disclosed
EP-2600904-A1 ARTIFICIAL CELLS Searete LLC (US) 2013-06-12 EP disclosed
US-8211656-B2 Biological targeting compositions and methods of using the same THE INVENTION SCIENCE FUND I, LLC (US) 2012-07-03 US disclosed
EP-1357912-B9 PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION QUADRA LOGIC TECH INC (CA) 2012-06-13 EP disclosed
US-20120134975-A1 Biological targeting compositions and methods of using the same SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE 2012-05-31 US disclosed
EP-1357912-B1 PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION QUADRA LOGIC TECH INC (CA) 2012-04-25 EP disclosed
WO-2002064163-A2 REDUCTION OR PREVENTION OF PDT RELATED INFLAMMATION QLT INC. (CA) 2002-08-22 WO disclosed
WO-2002062386-A2 PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION QLT INC. (CA) 2002-08-15 WO disclosed
WO-2002062384-A2 REDUCED FLUENCE RATE PDT QLT INC. (CA) 2002-08-15 WO disclosed
WO-2002062385-A2 METHOD TO PREVENT VISION LOSS QLT, INC. (CA) 2002-08-15 WO disclosed
EP-1229937-A2 USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA QLT Inc. (CA) 2002-08-14 EP disclosed
US-20020061330-A1 Supports for photosensitizer formulations BRITISH COLUMBIA, THE UNIVERSITY OF (CA) 2002-05-23 US disclosed
US-20020022032-A1 Immuno-adjuvant PDT treatment of metastatic tumors QLT INC. (CA) 2002-02-21 US disclosed
WO-2001085213-A2 SUPPORTS FOR PHOTOSENSITIZER FORMULATIONS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2001-11-15 WO disclosed
WO-2001085212-A2 DRUG DELIVERY SYSTEMS FOR PHOTODYNAMIC THERAPY THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2001-11-15 WO disclosed
WO-2001035996-A2 USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA QLT INC. (CA) 2001-05-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061330-A1 Supports for photosensitizer formulations PPOX, PPIF, SDHA MAPT 1710/4885MEN1 2343/4885KMT2A 2286/4885
US-20160205925-A1 ANTIMICROBIAL COMPOSITIONS MADE OF A THERMOPLASTIC POLYMER AND A PHOTOSENSITIZER CUTA, POLR1C, PUF60 MAPT 541/4885MEN1 3022/4885KMT2A 3422/4885
US-20020022032-A1 Immuno-adjuvant PDT treatment of metastatic tumors CD74, ANXA11, ANXA1 MAPT 1243/4885MEN1 2685/4885KMT2A 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.